Sherwood News

Chinese IPOs in the US have been making a comeback... of sorts

Even with ~$6 billion tea giant Chagee now in the mix, the current landscape still seems to be deterring bigger names.

4/23/25 9:38AM

Strange as the timing may seem, given the broader geopolitical picture, many Chinese companies are seeing 2025 as the year to hit the US public market. Last week, tea giant Chagee soared 21% on its Nasdaq debut to hit a $6.2 billion valuation, while a flurry of tech firms are reportedly looking to follow suit, per Bloomberg.

Red wave

Chagee’s $411 million raise last Thursday made it the largest Chinese consumer company listing in the US since 2021, momentarily bucking the drought of big Chinese initial public offerings that had been attributed to deteriorating relations between the two nations. Still, even against the backdrop of President Trump’s ongoing tariffs, postponed IPOs from other companies, and talk of Chinese stocks being delisted from US exchanges, 2025 has largely picked up where last year left off in terms of enticing companies looking to list in the US.

There was once a time when Chinese tech companies deciding to go public in America would shake Wall Street, like e-commerce behemoth Alibaba’s IPO in 2014, which initially raised $21.8 billion and was later valued at $25 billion, making it the largest in history at the time. While a host of companies followed suit, the surge wasn’t to last: after Chinese ride-hailing company DiDi Global decided to go public on the NYSE in 2021 — despite not getting the green light from Beijing regulators — it was forced to delist by the Chinese government, complicating the listing process ever since.

The tide has been slowly shifting recently, with Chinese offerings on the US market up almost 47% in 2024 compared to the year before, per data from US-China Economic and Security Review Commission (USCC). However, the precarious regulatory landscape was clearly a hurdle that many bigger companies were wary of even before the latest tariffs, with the 37 offerings in 2024 worth just $1.9 billion, down from $10.7 billion just four years earlier.

Interestingly, there had already been 11 offerings from companies based in Shanghai, Beijing, and beyond by March 7 this year, according to the USCC, as China’s government continues to boost and protect its domestic businesses.

Luke Kawa

45m

OpenAI’s cash burn suggests selling Nvidia because of reported Broadcom chip orders may not make much sense

When Broadcom announced that it booked $10 billion in new orders from a customer reported to be OpenAI, shares of their major AI chip rivals tanked.

The judgement of the Invisible Hand was that this was nearly a zero-sum outcome: $130 billion of market cap erased from Nvidia and Advanced Micro Devices, and a $135 billion increase in Broadcom’s market value.

But looking at this from the perspective of near-term cash flows, the market’s view seems off.

The Information is reporting that OpenAI now expects to burn through $115 billion by the end of 2029 (or more than 11 seasons’ worth of NFL broadcasting rights).

Let’s zoom in on this tidbit from The Information:

But the biggest change emerging from OpenAI’s latest projections was to its cash flows. The company projected it will burn more than $8 billion this year, or roughly $1.5 billion higher than its prior projection from earlier this year. Cash burn will more than double to more than $17 billion next year—$10 billion higher than what the company earlier projected

That $10 billion fits all too neatly with the $10 billion in orders from a major new customer that Broadcom CEO Hock Tan pointed to in the chip designer’s earnings call.

(Cheers to @lokoyacap for flagging this on X)

Assuming the reporting around OpenAI and Broadcom is accurate, these orders for ASICs don’t look to be displacing what the ChatGPT creator was going to spend on Nvidia’s GPUs, but are just in addition to it! The money’s not coming out of Jensen Huang’s pockets, it’s coming out of OpenAI’s coffers. Their spending budget is just getting bigger.

Perhaps if you squint, there’s a world in which OpenAI may prefer to have an additional $10 billion in Nvidia GPUs rather than ASICs, and I am still of the belief that hyperscalers diversifying their chip sources due to constrained top-end supplies isn’t a good sign for the company selling the most in-demand product.

But it’s quite intriguing, and says something about the depth of the pockets that fuel the AI boom, that OpenAI’s reported new relationship with Broadcom has seemingly no direct negative financial impact on Nvidia in the near term.

Luke Kawa

Broadcom’s post-earnings romp continues on heavy volumes

As Broadcom enjoys a rush of new orders from a major new customer (reported to be OpenAI), it’s also reveling in a flood of traffic into the stock.

Volumes are running at 2.5 times their daily average through 1:20 p.m. ET as traders continue to bid up shares in response to the brighter outlook for 2026 revenues, which sent the stock up 9.4% on Friday.

The chip designer is basking in a flood of price target hikes from Wall Street, with Bank of America, JPMorgan, Argus Research, Citigroup, Bernstein, Deutsche Bank, Morgan Stanley, Barclays, Piper Sandler, Rosenblatt Securities, Wells Fargo, and Susquehanna upping their view on how high shares can go since the company reported earnings last week.

Separately, Taiwanese industry outlet DigiTimes is reporting that orders from several other leading tech companies for custom-made Broadcom chips (or ASICs) are “already in the pipeline.” This report has not been corroborated by our own or any other publication’s reporting to date.

Matt Phillips

SpaceX spectrum deal sends would-be rivals lower

Shares of struggling satellite services company EchoStar soared Monday, after the company — which had recently tottered close to bankruptcy — announced the sale of some of its wireless spectrum licenses to Tesla CEO Elon Musk’s SpaceX for $17 million.

The sale provides a competitive advantage to Musk’s growing Starlink satellite services business, as the licenses it is acquiring from Echostar allows Starlink to operate ground based broadband and cellphone services, the Wall Street Journal reported.

Entities that stood to be hurt by the emergence of a Musk-led SpaceX Starlink service got hit hard on the news. AST SpaceMobile, which has plans to offer a similar satellite-to-consumer cellular service, tumbled.

So did wireless tower providers like Crown Castle and American Tower. Low cost cellular service provider T-Mobile, which had a deal with SpaceX, also slumped, as Luke noted earlier, along with other large wireless telecommunication services providers.

The wireless telecommunications industry grouping within the S&P 500 was down more than 2.5% shortly after noon, making it the worst performing industry within the S&P 500 on Monday.

SpaceX strikes $17B deal to buy EchoStar's spectrum for Starlink's direct-to-phone service | TechCrunch

The wireless telecommunications industry grouping within the S&P 500 was down more than 2.5% shortly after noon, making it the worst performing industry within the S&P 500 on Monday.

Robinhood, Amcor, Applovin surge on after being added to S&P 500

Robinhood, AppLovin vault higher as the "inclusion effect" is in full force

Membership has its privileges.

Matt Phillips5h

J. Edward Moreno

Hims rises, Novo dips after FDA releases “green list” of GLP-1 raw material suppliers

Hims & Hers rose and Novo Nordisk slipped in early trading after the US Food and Drug Administration released a "green list" of foreign GLP-1 ingredient suppliers that it considers in compliance with agency standards.

Some telehealth companies like Hims sell copycat versions of Novo's and Eli Lilly’s blockbuster weight-loss drugs through compounding pharmacies, which take the active ingredients from FDA-approved medications and make adjusted, or "personalized,” versions of the drug for patients.

Novo and Lilly have fought against this, arguing that it infringes on their intellectual property. They've sued smaller telehealth providers, pharmacies, and clinics in lieu of any action against them from the FDA. Instead, the FDA gave compounders a list of suppliers it deems safe.

Recent developments in the cases filed by the drugmakers so far as well as the FDA's recent actions suggest telehealth companies may be in a less risky position than investors previously thought. As of Monday morning, prediction markets pegged the likelihood of a suit from Novo against Hims at 34%, down from about 70% earlier this month.